Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes extended half-life antibody candidates targeting alpha4beta7, TL1A, and IL-23, which are being evaluated as monotherapies and pairwise fixed-dose combinations. Key investigational products include SPY001, SPY002, SPY003, and SPY072. Spyre focuses on optimizing potency, selectivity, and pharmacokinetics to enable subcutaneous maintenance dosing. The company is expanding its anti-TL1A program into indications such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Its therapeutic approach addresses unmet needs in immune-mediated diseases by improving efficacy, safety, and dosing convenience for patients.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage spyre.com
Sector Healthcare IR page ir.spyre.com
Tags
inflammatory bowel disease, rheumatic diseases, antibody therapeutics, long-acting antibodies, immune-mediated diseases, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, clinical-stage, subcutaneous dosing, SPY001, SPY002, SPY003, SPY072, SKYLINE, SKYWAY
Press page —

Metrics

Valuation  
Market cap $ 8.238B
Market cap (USD) $ 8.238B
P/E -31.22
PEG —
P/BV 7.83
P/S —
P/OCF -33.04
P/FCF -48.67
Dividend yield —
Turnover / mcap —
Returns  
ROE -25.2%
ROI -21.7%
ROIC -22.0%
Profit margin —
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score -71.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 0 0 886K 2.329M 18.739M 0 0 3.888M — — —
Net profit -155.203M -208.018M -338.79M -83.815M -65.801M -80.893M -78.254M -44.348M -27.236M -21.698M -11.295M
Free cash flow -169.252M -157.41M -99.91M -80.182M -54.289M -80.055M -67.184M -32.615M -25.234M -19.052M -11.19M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 32.76 23.28 21.52 0.45 4.75 7.87 7.64 7.49 5.41 4.35 —
Price performance 12m 0.41 0.08 46.83 -0.91 -0.4 0.03 0.02 0.38 0.24 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 5.12M 5.52M 5.48M 4.65M 0.00 — —
Cash and deposits (USD) 47.7M 12.8M 22.5M 19.3M 90.1M 15.1M 34.9M 189M 89.4M 85.7M
Right-of-use assets (USD) — — — 4.73M 4.23M 3.81M 3.43M 0.00 — —
Cash flow detail
Operating cash flow (USD) -18.8M -24.6M -32.2M -65.7M -75.8M -53.7M -80.1M -99.9M -157M -169M
Purchases of property, plant and equipment (USD) -212,000 -619,000 -422,000 -1.49M -4.28M -573,000 -38,000 0.00 0.00 —
Change in receivables (cash effect) (USD) 482,000 -1.86M 3.08M 0.00 0.00 -815,000 440,000 375,000 0.00 0.00
Change in payables (cash effect) (USD) -8,000 164,000 239,000 2.58M -544,000 1.07M -2.64M — — —
Income taxes paid (cash effect) (USD) — — — — — — — — — 15,000
Share-based compensation (USD) 1.22M 2.49M 4.28M 4.88M 6.26M 8.04M 7.11M 25.7M 44.8M 37.6M
Operating cash flow before change in receivables (USD) -19.3M -22.8M -35.3M -65.7M -75.8M -52.9M -80.6M -100M -157M -169M
Free cash flow (OCF - PPE - intangibles) (USD) -19.1M -25.2M -32.6M -67.2M -80.1M -54.3M -80.2M -99.9M -157M —
Income detail
Research and development expense (USD) 18.1M 22.8M 36.7M 64.6M 59.6M 57.1M 58.6M 89.5M 163M 172M
↳ 5y CAGR +56.7% +39.1% +25.8% +20.8% +19.5% +20.3% +23.5%
Total comprehensive income (USD) -21.7M -27.3M -44.3M -78.2M -80.9M -65.8M -83.8M -338M -208M -155M
Comprehensive income to owners (USD) -21.7M -27.3M -44.3M -78.2M -80.9M -65.8M -83.8M -338M -208M -155M
Reported Mar 23, 2017 Mar 13, 2018 Mar 7, 2019 Mar 8, 2022 Mar 8, 2022 Mar 8, 2022 Mar 2, 2023 Feb 29, 2024 Feb 27, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 6, 2026

PDF Version

WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 11,138 shares of common stock of Spyre and 3,195 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on November 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $95.51, the closing price per share of Spyre's common stock as reported by Nasdaq on November 2, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4th) of the shares subject to the respective RSUs on each anniversary of the next November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

November 3, 2026

PDF Version

Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is enrolling ahead of schedule, enabling the Company to increase enrollment and provide topline induction results for three potential best-in-indication combinations, which are expected in Q3 2027

Reported positive topline results for SPY072 in rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial (“SKYWAY”), though with a magnitude of benefit insufficient to prioritize advancement. SPY072 was well-tolerated but did not meet its primary endpoint in the psoriatic arthritis (“PsA”) or axial spondyloarthritis (“axSpA”) SKYWAY sub-studies. SPY072 will not be advanced in rheumatic disease

Initiated a new Phase 2 trial (“SKYLIGHT”) designed to provide clinical proof-of-concept for dual TL1A and IL-17A/F inhibition in hidradenitis suppurativa (“HS”). Raised over $400 million in gross proceeds from an underwritten public offering in October to fund a pivotal program in HS with SPY072, our potential best-in-class TL1A monotherapy

$1.5 billion in pro forma cash, cash equivalents, and marketable securities as of September 30, 2026, with expected runway into the second half of 2029

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced its third quarter 2026 financial results and provided program and corporate updates.

“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm. The combination portion of our SKYLINE trial is enrolling faster than expected enabling an increased enrollment target, and we plan to deliver topline data in Q3 2027 with the potential for efficacy, safety, and convenience that meaningfully surpasses today's standard of care,” said Cameron Turtle, DPhil, Chief Executive Officer of Spyre. “Beyond IBD, we were thrilled to see excellent external proof-of-concept data for TL1A in hidradenitis suppurativa, supporting the expansion of our pipeline to include a pivotal monotherapy program as well as a combination study with the current standard of care, IL17-A/F. Collectively, we believe the breadth of our pipeline, strength of our clinical data, and continued execution position Spyre to potentially deliver meaningful advances for patients across multiple large markets and substantial long-term value for shareholders.”

Development Pipeline Overview and Update

The Company is committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. The Company’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, IL-23 and IL-17A/F (each as defined below), as well as rational combination programs, in large therapeutic areas of focus, each with high unmet need.

  • In Gastroenterology, the Company is advancing three potential first- and best-in-class combination programs in inflammatory bowel disease (“IBD”). IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders: ulcerative colitis (“UC”) and Crohn's disease (“CD”). In the United States, it is estimated that approximately 2.4 million individuals are diagnosed with IBD and the global market is forecasted to exceed $40 billion by 2030.

  • In Dermatology, the Company is advancing a potential first- and best-in-class anti-TL1A + IL-17A/F combination program in hidradenitis suppurativa (“HS”). Additionally, the Company plans to advance a potential best-in-class anti-TL1A monotherapy agent into pivotal studies for HS in 2027. HS is a chronic inflammatory skin condition characterized by recurrent, painful nodules and abscesses, primarily in areas such as the underarms and groin. The disease can progress to draining tunnels and permanent scarring, substantially impacting patients’ quality of life. It is estimated that the disease affects approximately 3.0 million patients in the United States, with the global market forecasted to exceed $10 billion by 2035.

The Company has three ongoing Phase 2 clinical trials with meaningful proof-of-concept data readouts in 2026 and 2027:

**SKYLINE Phase 2 Platform Trial in IBD -**in May 2025, the Company initiated a Phase 2 induction and maintenance platform trial of SPY001 (long-acting anti-α4β7), SPY002 (long-acting anti-TL1A) and SPY003 (long-acting anti-IL-23), as well as pairwise combinations thereof (six investigational agents in total), in patients with moderately to severely active UC. The trial consists of two parts:

  • Part A: Open-label assessment of the safety and preliminary efficacy of a single dose level of each investigational monotherapy. Enrollment for Part A has completed, with initial SPY001, SPY002 and SPY003 Part A topline induction data announced in April 2026, June 2026, and September 2026, respectively.

  • SPY001, SPY002, and SPY003 were well-tolerated with a safety profile consistent with in-class comparators. SPY001, SPY002, and SPY003 all achieved their respective primary endpoints, demonstrating a statistically significant reduction in the Robart’s Histopathology Index (“RHI”) score of 9.2 points, 10.7 points, and 10.0 points, respectively. Rates of key secondary endpoints of clinical remission and endoscopic improvement were clinically meaningful at 40% and 51%, respectively, for SPY001, 33% and 42%, respectively, for SPY002, and 20% and 30%, respectively, for SPY003. The change in the modified Mayo Score from baseline at Week 12 for both SPY001 and SPY002 was -3.7, and for SPY003 was -3.5, reflecting consistency across secondary endpoints.

  • Part B: Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept, and contribution of components for combinations, with induction data expected in the third quarter of 2027. Study is enrolling ahead of schedule enabling an increased enrollment target.

**SKYLIGHT Phase 2 Trial in HS -**in September 2026, the Company initiated its SKYLIGHT Phase 2 trial of SPY072 in subjects with moderately to severely active HS who are initiating bimekizumab. The trial serves as a surrogate proof-of-concept study for the Company’s internal SPY772 combination program combining SPY072 (long-acting anti-TL1A) and SPY007 (long-acting anti-IL-17A/F). Topline Week 16 results are planned in late 2027 or early 2028.

**SKYWAY Phase 2 Basket Trial in Rheumatic Diseases -**in September 2025, the Company initiated a Phase 2 randomized and placebo-controlled basket trial of SPY072 in patients with moderately to severely active RA, PsA, or axSpA. The trial consists of three sub-studies:

  • RA sub-study: Double-blind, placebo-controlled safety and efficacy study of two dose levels of SPY072 at Week 12 with open-label follow-up through Week 36. Topline proof-of-concept data were released in August 2026. Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (ACR50). SPY072 was well tolerated, with a safety profile consistent with the TL1A class. While SPY072 demonstrated clinical activity in RA, the results did not meet the Company’s internal bar to prioritize advancement of SPY072 in RA.

  • PsA and axSpA sub-studies: Double-blind, placebo-controlled safety and efficacy studies of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. The Company announced that SPY072 was well-tolerated, but neither sub-study met its primary endpoint of ACR20 response in PsA or change from baseline in ASDAS in axSpA.

The Company does not plan to advance SPY072 in rheumatic diseases.

The investigational therapies being studied in the Company’s clinical trials include:

SPY001 – a highly potent and selective investigational monoclonal antibody targeting the α4β7 integrin (“α4β7”), engineered with half-life extension technology and formulated at high concentration with the goal of maximizing efficacy and enabling infrequent, subcutaneous maintenance dosing. SPY001 is being evaluated for the treatment of IBD in the SKYLINE study.

SPY002 and SPY072 – two highly potent and selective, investigational anti-tumor necrosis factor-like ligand 1A (“TL1A”) monoclonal antibodies, engineered with half-life extension technology and formulated at high concentration with the goal of maximizing efficacy and enabling infrequent, subcutaneous maintenance dosing. The Company believes TL1A has emerged as one of the most promising targets in IBD and broader immunology indications. SPY002 is being evaluated for the treatment of IBD in the SKYLINE study and SPY072 is being developed for the treatment of HS, both as a monotherapy and as part of a combination.

SPY003 – a highly potent and selective investigational monoclonal antibody targeting the p19 subunit of interleukin 23 (“IL-23”), engineered with half-life extension technology and formulated at high concentration with the goal of maximizing efficacy and enabling infrequent, subcutaneous maintenance dosing. SPY003 is being evaluated for the treatment of IBD in the SKYLINE study.

SPY007 – a preclinical-stage program designed to bind to interleukin 17A (“IL-17A”) and interleukin 17F (“IL-17F”), while incorporating half-life extending modifications. SPY007 is being developed for the treatment of HS in combination with SPY072.

Rational Combinations (SPY120, SPY130, SPY230, and SPY772) – the Company is investigating combinations of its proprietary antibodies in clinical trials in order to evaluate whether combinations can potentially lead to best-in-class efficacy in several inflammatory diseases, with less frequent dosing.

  • The Company is currently enrolling its SPY120, SPY130, and SPY230 combinations in Part B of the SKYLINE trial, with an expected induction read-out in 2027.

  • The Company’s SPY772 combination program aims to target multiple inflammatory pathways involved in HS, pairing its novel anti-TL1A (SPY072) with SPY007, its anti-IL-17A/F. The goal is to use this long-acting, co-formulated combination in future advanced clinical development, pending the results from the Company’s SKYLIGHT proof-of-concept trial.

Third Quarter 2026 Financial Results

Cash Position: As of September 30, 2026, Spyre had cash, cash equivalents, and marketable securities of $1,071.9 million. Pro forma cash of $1,467.9 million as of September 30, 2026, with expected runway into the second half of 2029, also reflects $378.0 million in net proceeds from the recently closed October 2026 underwritten public offering of common stock and $18.0 million in October 2026 at-the-market (ATM) sales. Net cash used in operating activities was $77.5 million for the third quarter of 2026.

Research and Development (R&D) expenses: R&D expenses totaled $89.2 million for the third quarter of 2026 and $45.2 million for the third quarter of 2025. The increase was primarily driven by higher manufacturing costs and clinical trial expenses.

General and Administrative (G&A) expenses: G&A expenses totaled $16.6 million for the third quarter of 2026 and $11.6 million for the third quarter of 2025. The increase was primarily driven by increased headcount and professional services fees.

Total Other Income (Expense): Other income totaled $9.6 million for the third quarter of 2026 compared to $45.7 million of total other income in the third quarter of 2025. The change was primarily due to changes in the fair value of the contingent value right (“CVR”) liability in the prior period.

**Net Loss:**Net loss totaled $96.1 million and $11.2 million for the third quarters of 2026 and 2025, respectively.

About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

October 18, 2026

PDF Version

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms.

“Despite significant advances in the treatment of IBD, many patients still do not achieve or maintain the level of disease control we would like to see, underscoring the need for new approaches that can deliver deeper and more durable responses,” said Silvio Danese, M.D., Ph.D., Professor of Gastroenterology at Vita-Salute San Raffaele University and Head of the Gastroenterology and Endoscopy Unit at IRCCS San Raffaele Hospital in Milan, and Chair of the SKYLINE trial Steering Committee. “We believe that advanced combination therapy provides a strong probability of enhanced efficacy compared to today’s monotherapies, and Spyre’s approach of combining optimized versions of antibodies against proven targets represents one of the most promising pipelines in the field. With clinical proof-of-concept now demonstrated across SPY001, SPY002 and SPY003, we are increasingly excited to see the combination results next year with the potential to raise the therapeutic ceiling for patients with IBD.”

The poster and presentation will be available for viewing during UEGW, and details are as follows:

Oral Presentation

Title: Efficacy and Safety of Half-Life Extended Antibodies SPY001, SPY002, and SPY003 for Induction Treatment of Moderately to Severely Active Ulcerative Colitis Abstract Session: Hot Topics in IBD Presentation Date/Time: Sunday, Oct. 18,15:30-15:40 CEST Presentation Location: Room B3 **Presenter:**Silvio Danese, M.D., Ph.D., San Raffaele Hospital

Moderated Poster

Title: Anti-α4β7 integrin, anti-TL1A, and anti-IL-23 are efficacious in TNBS-induced colitis using humanized mice, and combinations further improve efficacy Poster Session: New Insights into IBD Biology (II) Session Date/Time: Monday, Oct. 19, 16:06-16:12 CEST Presentation Location: Hall 7, Poster Stage 2 Presenter: Andy Spencer, Ph.D., Spyre Therapeutics

Full session details can be accessed via the UEGW program.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

Prompts

Spyre Therapeutics, Inc. (ticker SYRE), listed in United States.

Company History

Date Change Detail
Aug 28, 2023 Renamed AEGLEA BIOTHERAPEUTICS, INC. → SPYRE THERAPEUTICS, INC.
— Former tickers AGLE

ETFs Holding Spyre Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 6.70% 94,677 $ 8.457M Aug 31, 2026
QMOM 2.44% 99,082 $ 9.29M Nov 18, 2026
MMSC 1.21% 6,095 $ 605.66K Nov 16, 2026
GDOC 0.77% 1,690 $ 150.968K Aug 31, 2026
MEDI 0.70% 3,207 $ 330.032K Nov 12, 2026
GSC 0.61% 19,011 $ 1.698M Aug 31, 2026
ESSC 0.55% 2,023 $ 198.922K Jul 31, 2026
SCDS 0.49% 477 $ 44.747K Nov 17, 2026
JDOC 0.47% 492 $ 46.155K Nov 17, 2026
FMED 0.45% 2,600 $ 232.258K Aug 31, 2026
CGMM 0.42% 153,656 $ 15.269M Nov 16, 2026
FTKI 0.29% 751 $ 74.627K Nov 16, 2026
RUSC 0.25% 2,223 $ 197.358K Jun 30, 2026
RESM 0.22% 90 $ 7,990.20 Jun 30, 2026
TMED 0.20% 525 $ 46.61K Jun 30, 2026
VFMO 0.18% 39,212 $ 3.503M Aug 31, 2026
MSSM 0.18% 14,295 $ 1.277M Aug 31, 2026
IALT short -0.10% -76,579 $ -7.61M Nov 16, 2026
JGRO 0.10% 98,071 $ 9.2M Nov 17, 2026
TMSL 0.09% 27,295 $ 2.423M Jun 30, 2026
AVIE 0.06% 105 $ 10.434K Nov 16, 2026
AVLC 0.01% 1,909 $ 189.697K Nov 16, 2026
AVUS 0.00% 351 $ 34.879K Nov 16, 2026